COPD is Associated with Higher Prevalence of Back Pain: Results of a Population-Based Case–Control Study, 2017

Marta Fuentes-Alonso1
Ana López-de-Andrés2
Domingo Palacios-Ceña3
Rodrigo Jimenez-Garcia4
Marta Lopez-Herranz5
Valentin Hernandez-Barrera6
Napoleon Perez-Farinos6
Zichen Ji1
Javier de-Miguel-Diez1

1Respiratory Department, Hospital General Universitario Gregorio Marañón, Facultad de Medicina, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), Madrid, Spain; 2Department of Medical Specialties and Public Health, Universidad Rey Juan Carlos, Madrid, Spain; 3Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical Medicine, Research Group of Humanities and Qualitative Research in Health Science of Universidad Rey Juan Carlos (Hum&QrHs), Universidad Rey Juan Carlos, Madrid, Spain; 4Department of Public Health & Maternal and Child Health, Faculty of Medicine, Universidad Complutense de Madrid, Madrid, Spain; 5Faculty of Nursing, Physiotherapy and Podology, Universidad Complutense de Madrid, Madrid, Spain; 6Department of Public Health and Psychiatry, Faculty of Medicine, Universidad de Málaga, Málaga, Spain

Objective: We aimed to assess whether patients suffering from COPD have a higher prevalence of chronic back pain (neck and low back pain) than age-, sex-, and residence-matched non-COPD controls. We also aimed to identify which variables are associated with chronic neck pain (CNP) and chronic low back pain (CLBP) among COPD patients.

Methods: We carried out a retrospective case–control study using data obtained from the Spanish National Health Survey conducted in 2017.

Results: We analyzed data from 1034 COPD and 1034 matched non-COPD controls. The prevalence of CNP and CLBP was 38.20% and 45.16%, respectively, among COPD patients and 22.82% and 28.34% for non-COPD controls, respectively (p<0.001 for both). Multivariable analysis showed that COPD patients had a 1.62-fold (95% CI 1.50–1.74) higher risk of CNP and a 1.83-fold (95% CI 1.73–1.91) higher risk of CLBP than non-COPD controls. Experiencing one type of pain greatly increased the risk of having the other. Factors associated with the presence of both types of pain among COPD patients included female sex, “fair/poor/very poor” self-rated health, migraine or frequent headache and use of pain medication. Being aged from 70 to 79 years was a risk factor for CLBP, and suffering from a mental disorder was a risk factor for CNP.

Conclusion: The prevalence of CNP and CLBP was significantly higher among COPD patients than among non-COPD controls after adjusting for age, sex and other relevant clinical variables. Our findings add new data to the knowledge of chronic pain in COPD patients.

Keywords: COPD, neck pain, low back pain, comorbidities, pain medication

Introduction

Chronic obstructive pulmonary disease (COPD) is a common, preventable and treatable condition that is characterized by persistent and often progressive airflow limitation, mainly associated with tobacco smoking. It is a leading cause of morbidity and mortality worldwide and induces a substantial economic and social burden. In addition, the prevalence and burden of COPD are projected to increase over the coming decades due to continued exposure to COPD risk factors and aging of the world population.1

Symptoms, including dyspnea, cough, and sputum production, are relatively common in COPD patients and constitute risk factors for poor health-related quality of life and a decrease in their physical activity.2 Most recently, chronic pain has been reported as a frequent symptom in these patients, in addition to the previous...
ones, and in turn, it can have a negative impact on the degree of dyspnea, physical activity, and quality of life of these patients.\(^3\)

Pain in patients with COPD can have different causes. Low back pain is one of the most common localizations.\(^4\) Other body localizations of pain in these patients are the neck, trunk, and limbs.\(^5-7\) The potential mechanisms that can cause, contribute to, or maintain this symptom in individuals with COPD include the mechanical limitations of the movement of the chest wall as a result of hyperinflation, musculoskeletal disorders, postural deviations, osteoporosis, compression fractures, vertebral deformations, costovertebral arthropathy, side effects of prolonged use of steroids, the presence of comorbidities, and certain individual characteristics, such as gender and socioeconomic factors.\(^8\)

The incidence, severity, and risk factors for pain in patients with COPD are rather heterogeneous.\(^9\) The prevalence rates for pain range between 21% and 82% among COPD patients, depending on factors such as the clinical context of the study population, sampling source, measurement instrument and study period.\(^8\) Regarding severity, it has been reported that the pain experienced by COPD patients is stronger than that perceived by those without a respiratory disease or by patients with other chronic diseases\(^10\) and is comparable to the pain observed in oncologic patients at the terminal stage.\(^4,11\) However, in the few studies that have been conducted so far, various methods have been used to assess pain in COPD patients, which could lead to misinterpretation of the phenotype of this symptom and justify the wide range in the estimated prevalence of pain that has been reported.\(^12\) Regarding risk factors, a recent study has highlighted the influence of age, sex, blood pressure, and obesity in some types of pain suffered by these patients.\(^13\) Nevertheless, the role of other comorbidities in the presence of pain in COPD remains controversial.\(^14\)

These limitations highlight the need for additional research on the prevalence and characteristics associated with the occurrence of pain in COPD patients. Improving knowledge of these aspects is important and necessary to improve pain recognition and treatment in individuals with this disease.

Using the Spanish National Health Survey conducted in 2017 (SNHS2017), we aimed to assess whether patients suffering from COPD have a higher prevalence of chronic back pain (neck and low back pain) than age-, sex-, and residence-matched non-COPD controls. We also aimed to identify which variables are associated with chronic neck pain (CNP) and chronic low back pain (CLBP) among COPD patients.

### Materials and Methods

#### Study Design

We designed a case–control study. The data used were obtained from the SNHS2017 conducted in Spain from October 2016 to October 2017. Details in the methodology can be found elsewhere.\(^15\) Briefly, the SNHS2017 includes a representative sample of the Spanish population aged 15 years or older residing in main family dwellings. The sampling method is a stratified three-stage sampling: first stage units are the census tracts; the second stage units are the main family dwellings; in the third stage, an adult (aged ≥15 years) was randomly selected (Kish method) from each household to fill in the questionnaire.\(^15\)

The information collection method is computer-assisted personal interviews (CAPIs). For our investigation, we selected only persons aged 35 years or older. The reason for this cutoff point is the extremely low prevalence of COPD below this age.\(^16\)

#### Study Variables

In the SNHS2017, the self-reported presence of chronic conditions is collected using three consecutive questions: 1) Do you have or have you ever had any of the following diseases or health conditions? 2) Have you suffered this disease/health condition in the past 12 months? And 3) Was this disease/health condition been diagnosed by a doctor? A card with a list of 32 conditions is shown to the person interviewed after the first question, and for those conditions reported by the participant, the second and third questions are completed consecutively for each specific condition.

Participants were asked if they suffered COPD, and only persons who answered affirmatively to the three questions used to identify the presence of this disease were considered “COPD sufferers”. The same method was used to identify participants who suffered CNP and CLBP.

All participants were informed by the interviewer, prior to answering these questions, that a “chronic disease or health condition” is one that has lasted for at least 6 months.\(^15\)

The independent variables analyzed and their categories are detailed in Tables 1 and 2 and included age,
Table 1 Distribution According to Study Variable Among Patients with COPD and Age-Sex-Province of Residence-Matched Non-COPD Subjects

| Variables                        | Categories          | Non-COPD | COPD   | P       |
|----------------------------------|---------------------|----------|--------|---------|
|                                  | N       | %     | N       | %     |         |
| Educational level                | Secondary education | 127      | 12.28  | 135     | 13.06   | 0.230   |
|                                  | High education     | 162      | 15.67  | 135     | 13.06   |         |
| Monthly income                   | £800–1300         | 207      | 32.65  | 217     | 33.33   | 0.161   |
|                                  | >£1300            | 239      | 37.69  | 215     | 33.02   |         |
| Living with a partner            | Yes                | 578      | 55.89  | 563     | 54.45   | 0.473   |
| Self-rated health                | Very good         | 546      | 52.83  | 251     | 24.27   | <0.001  |
|                                  | good              |          |        |         |         |         |
| Asthma                           | Yes                | 42       | 4.06   | 285     | 27.57   | <0.001  |
| Heart disease*                   | Yes                | 122      | 11.80  | 220     | 21.28   | <0.001  |
| Diabetes                         | Yes                | 174      | 16.83  | 243     | 23.50   | <0.001  |
| High blood pressure              | Yes                | 415      | 40.14  | 460     | 44.48   | 0.045   |
| Cancer                           | Yes                | 38       | 3.68   | 65      | 6.29    | 0.109   |
| Mental disorders*                | Yes                | 139      | 13.44  | 272     | 26.31   | <0.001  |
| Migraine or frequent headache    | Yes                | 75       | 7.26   | 154     | 14.85   | <0.001  |
| Body mass index                  | 25–29.9 kg/m²      | 437      | 42.27  | 384     | 37.14   | <0.001  |
|                                   | ≥30                | 197      | 19.05  | 296     | 28.63   |         |
| Physical exercise                | 4–7 days           | 348      | 33.66  | 338     | 32.69   | 0.640   |
| Tobacco use                      | Ex-smoker          | 339      | 32.78  | 396     | 38.30   | <0.001  |
|                                  | Current smoker     | 157      | 15.19  | 207     | 20.02   |         |
| Alcohol consumption              | Yes                | 378      | 36.57  | 390     | 37.72   | 0.585   |
| Pain intensity                   | Moderate           | 211      | 20.52  | 279     | 36.76   | <0.001  |
|                                  | Severe/            | 120      | 20.20  | 252     | 33.14   |         |
| Use of pain medication           | Yes                | 375      | 44.32  | 555     | 56.38   | <0.001  |
| Chronic neck pain                | Yes                | 236      | 22.82  | 395     | 38.20   | <0.001  |
| Chronic low back pain            | Yes                | 293      | 28.34  | 467     | 45.16   | <0.001  |

Notes: P value obtained comparing COPD vs matched non-COPD controls; *Heart disease included coronary disease, myocardial infarction and angina; †Mental disorder included anxiety and/or depression; ‡Body mass index bases on self-reported height and weight; §Physical exercise. Days per week with walking for at least 10 minutes; ‡Alcohol consumption. If the subject has consumed alcohol two or more times a month over the last year; ²Pain intensity in the last 4 weeks; ³Consumption of physician-prescribed pain medication in last 2 weeks.

The same methods used to identify those with COPD, CNP and CLBP were used to determine the presence of self-reported asthma, heart disease, diabetes, high blood pressure, cancer, mental disorders (anxiety and/or depression) and migraine or frequent headache. Lifestyle variables included body mass index, physical exercise, tobacco use and alcohol consumption.

All the questions included in the SNHS2017 and explanations on how the questionnaires are conducted are described elsewhere.15,17

Case–Control Design

The prevalence of COPD among those aged 35 years or over in the SNHS2017 was 5.99%, with a mean age of 68.29 years (SD 13.58, SEM 0.623, CR 0.189). The mean age for those without COPD was significantly lower (p<0.001), 46.58 years (SD 18.58 SEM 0.399, CR 0.189). Given this large difference, it is necessary to match COPD patients with non-COPD subjects to obtain comparable populations. To do this, for every person with COPD (patient), we used the SNHS2017 database to identify a participant without COPD (control) with exactly the same age, sex and residence as the control. If more than one control was available for a patient, the selection was done randomly. We were able to find a matched control for each of the 1034 COPD participants identified in the SNHS2017.

Statistical Analysis

All results are shown and compared according to the presence of COPD. We estimated the prevalence of CNP and CLBP according to the study variables. As descriptive statistics for quantitate variables, we used means, standard deviations, standard error of the mean (SEM) and coefficient of variation (CV) and for qualitative variable proportions. To compare proportions between matched patients and controls, we used the McNemar test. A paired Student’s t-test was used to compare means. To assess the association between the study variables and the presence of CNP and CLBP within the two study populations (patients and controls), we used the Chi square test.

Multivariable conditional logistic regression models were constructed to estimate the risk of suffering CNP and CLBP among COPD patients versus non-COPD controls after adjusting for possible confounders.

Unconditional logistic regression models were used to identify which variables were independently associated with self-reported CNP and CLBP among COPD sufferers.

sex, educational level, monthly income, living with a partner and self-rated health. The pain characteristics analyzed were pain intensity and the use of pain medication prescribed by a physician.
Table 2 Prevalence of Chronic Neck Pain and Chronic Low Back Pain Among COPD Subjects and Non-COPD Controls According to Pain Characteristics, Health Status and Lifestyles Variables

|                                       | Chronic Neck Pain | Chronic Low Back Pain |
|---------------------------------------|-------------------|-----------------------|
|                                       | Non-COPD          | COPD                  | Non-COPD          | COPD                  |
|                                       | N     | %    | N     | %    | N     | %    | N     | %    |
| Concomitant chronic neck paina, d     | No    | NA   | NA    | NA   | 91    | 31.06| 141   | 30.16|
|                                       | Yes   | NA   | NA    | NA   | 192   | 65.53| 326   | 69.81|
| Concomitant chronic low back painc, d | No    | 42   | 17.79 | 69    | 17.47 | NA   | NA    | NA    |
|                                       | Yesa  | 182  | 77.12 | 326   | 82.53 | NA   | NA    | NA    |
| Pain intensityac                      | Lightb       | 52   | 19.77 | 61    | 26.64 | 68   | 25.86 | 84    | 36.68|
|                                       | Moderateb     | 91   | 34.13 | 134   | 48.03 | 107  | 50.71 | 157   | 56.27|
|                                       | Severe/extreme, b | 65   | 54.16 | 160   | 63.61 | 72   | 62.22 | 180   | 71.67|
| Use of pain medicationac              | Noa, b      | 65   | 13.80 | 91    | 21.36 | 75   | 15.92 | 118   | 27.00|
|                                       | Yesa, b      | 157  | 41.87 | 293   | 52.79 | 200  | 53.33 | 335   | 60.36|
| Migraine or frequent headacheac       | Noa, b      | 198  | 83.89 | 218   | 72.66 | 239  | 84.98 | 338   | 72.38|
|                                       | Yesa, b      | 38   | 16.11 | 108   | 27.34 | 44   | 15.02 | 129   | 27.62|
| Self-rated healthac                   | Fair/poor/very poor, b | 171  | 35.04 | 343   | 43.81 | 207  | 42.42 | 408   | 52.11|
|                                       | Very good/good, b | 65   | 11.90 | 52    | 20.72 | 86   | 15.75 | 59    | 23.51|
| Asthmaac                              | Noa, b      | 224  | 22.58 | 264   | 35.25 | 282  | 28.43 | 314   | 41.92|
|                                       | Yesa         | 12   | 28.57 | 131   | 45.96 | 11   | 26.19 | 153   | 53.68|
| Heart diseaseac                       | Noa, b      | 202  | 22.15 | 282   | 34.64 | 249  | 27.30 | 351   | 43.12|
|                                       | Yesa, b      | 34   | 27.87 | 113   | 51.36 | 44   | 36.07 | 116   | 52.73|
| Diabetesac                            | Noa, b      | 195  | 23.56 | 299   | 37.80 | 246  | 28.60 | 342   | 43.24|
|                                       | Yesa         | 41   | 16.27 | 96    | 39.51 | 47   | 27.01 | 125   | 51.44|
| High blood pressureac                 | Noa, b      | 129  | 20.84 | 202   | 35.19 | 160  | 25.85 | 236   | 41.11|
|                                       | Yesa, b      | 107  | 25.78 | 193   | 41.96 | 133  | 32.05 | 231   | 50.22|
| Cancerac                              | Noa, b      | 221  | 22.19 | 363   | 37.46 | 277  | 27.81 | 438   | 45.20|
|                                       | Yesa, b      | 15   | 39.47 | 32    | 49.23 | 16   | 42.11 | 29    | 44.62|
| Mental disordersac                    | Noa, b      | 176  | 19.66 | 243   | 31.89 | 225  | 25.14 | 300   | 39.37|
|                                       | Yesa, b      | 60   | 43.17 | 152   | 55.88 | 68   | 48.92 | 167   | 61.40|
| Body mass index (kg/m²)d             | <25b        | 68   | 22.15 | 115   | 40.21 | 70   | 22.80 | 125   | 43.71|
|                                       | 25–29.9 b    | 99   | 22.65 | 126   | 32.81 | 122  | 27.92 | 155   | 40.36|
|                                       | ≥30b         | 48   | 24.37 | 123   | 41.55 | 73   | 37.06 | 150   | 50.68|
| Physical exerciseac                   | 0–3 daysa, b | 168  | 24.49 | 274   | 39.37 | 212  | 30.90 | 335   | 48.13|
|                                       | 4–7 daysa, b | 68   | 19.54 | 121   | 35.80 | 81   | 23.28 | 132   | 39.05|
| Tobacco useac                         | Nevera, b   | 142  | 26.39 | 189   | 43.85 | 164  | 30.48 | 225   | 52.20|
|                                       | Ex-smokera, b | 66   | 19.47 | 130   | 32.83 | 83   | 24.48 | 158   | 39.90|
|                                       | Current smoker, a, b | 28   | 17.83 | 76    | 36.71 | 46   | 29.30 | 84    | 40.58|
| Alcohol consumptionac                 | Noa, b      | 167  | 25.46 | 282   | 43.79 | 210  | 32.01 | 335   | 52.02|
|                                       | Yesa, b      | 69   | 18.25 | 113   | 28.97 | 83   | 21.96 | 132   | 33.85|

Notes: aSignificant difference (p<0.05) between COPD suffers and non-COPD sufferers for chronic neck pain; bSignificant differences (p<0.05) between COPD suffers and non-COPD sufferers for chronic low back pain. Comparisons conducted using McNemar test; cSignificant association (p<0.05) between the variable and chronic neck pain among COPD sufferers; dSignificant association (p<0.05) between the variable and chronic low back pain among COPD sufferers. Comparisons conducted using Chi square test.
Variables included in multivariable models were those significant in the bivariate analysis and those previously reported as relevant by the scientific literature. These models were conducted following the recommendation of Hosmer et al.18

The adjusted odds ratio (OR) with 95% confidence intervals (95% CI) is the measure of association provided by the multivariable models.

STATA 14.0 (StataCorp. 2015. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP, USA) was used for statistical analysis using the command “svy” for complex sample analyses. Significance was set at two-tailed $a < 0.05$.

**Ethical Aspects**

In accordance with the Spanish legislation, as we used a public access dataset with all data anonymous, it was not necessary to obtain the approval of an ethics committee. The database can be downloaded freely by anyone.19

**Results**

We analyzed data from 1034 COPD- and 1034 matched non-COPD controls. The distribution of the study populations is shown in Table 1. No differences in the sociodemographic characteristics analyzed were found between patients and controls after matching. COPD patients reported worse self-rated health and a higher prevalence of asthma, heart disease, diabetes, high blood pressure, mental disorders and migraine or frequent headache than non-COPD controls. Obesity and current smoking were more frequent (28.63% vs 19.05% and 20.02% vs 15.19%, respectively) among COPD patients ($p<0.001$).

Severe/extreme pain intensity and use of pain medication were also more prevalent in COPD subjects ($p<0.001$).

The prevalence of CNP and CLBP was 38.20% and 45.16% among COPD patients, respectively, and 22.82% and 28.34% among non-COPD controls, respectively ($p<0.001$ for both). After multivariable analysis, the ORs showed a significantly higher adjusted risk of self-reporting CNP (OR 1.62; 95% CI 1.50–1.74) and CLBP (OR 1.83, 95% CI 1.73–1.91) among COPD patients than non-COPD controls.

show the prevalence of CNP and CLBP among COPD subjects and non-COPD controls according to sociodemographic variables.

The prevalence of CNP and CLBP was significantly higher among COPD patients than among non-COPD controls for all the categories of the sociodemographic variables included in Figures 1–3.

Among COPD patients, the prevalence of CNP increased with age, from 34.30% in the lower age group to 42.08% in the highest. Women had two times higher values than men (50.85% vs 24.85%; $p<0.001$).

For CLBP, the highest prevalence among COPD patients was found in the age group of 70–79 years (51.70%), and the lowest was found in the age group of 35–59 years (39.71%). A total of 55.56% of women with COPD reported CLBP compared with 34.19% of non-COPD women ($p<0.001$).

As seen in Table 2, regarding pain characteristics, COPD sufferers with CNP or CLBP showed higher pain intensity, more use of pain medication and higher prevalence of migraine or frequent headache than controls. Compared with the controls, subjects with COPD had a higher prevalence of both CNP and CLBP for all the health status and lifestyle variables analyzed.

Among COPD controls, the prevalence of CNP was higher for those with worse self-rated health and suffering any of the diseases analyzed than among those with better self-rated health and not suffering these conditions. The highest prevalence of CNP for COPD patients was found among those suffering mental disorders (55.88%) and heart disease (51.36%).

Regarding lifestyles, a BMI of 30 kg/m$^2$ or over and practicing less physical exercise were variables associated with a higher prevalence of CNP among COPD sufferers.

COPD patients experienced more severe CLBP if they had worse self-rated health or any of the clinical conditions analyzed than COPD patients with better self-rated health and not experiencing these conditions.

CLBP was reported by 61.40% of COPD patients with mental disease and over half of those with concomitant asthma (53.68%), heart disease (52.73%), high blood pressure (50.22%) or BMI ≥30 (50.68%).

The predictors for CNP and CLBP among COPD patients after multivariable adjustment are shown in Table 3. For CNP and CLBP, the probability of reporting these pains was significantly higher among women, those with “Fair/poor/very poor” self-rated health, pain medication users and those who reported migraine or frequent headache.

For CNP, the risk increased significantly among COPD patients with mental disorders and among those who reported suffering concomitant CLBP.

Among COPD subjects, those aged 70–79 years old had a 1.67 times higher risk of CLBP than those aged...
35–59 years old. Finally, concomitant CNP was a risk factor for CLBP.

**Discussion**

Our study demonstrated that COPD patients had a significantly higher risk of CNP and CLBP than non-COPD controls. In addition, we observed that experiencing one type of pain greatly increased the risk of having the other among individuals with COPD. Moreover, COPD patients with CNP and CLBP showed higher pain intensity, more use of pain medication and higher prevalence of migraine or frequent headache than controls without COPD.

The prevalence of CNP and CLBP in our study is consistent with previous studies.\(^1\)\(^4\)\(^2\) Greater pain in the COPD population could be due to more prolonged induction of painful stimuli or possibly to lower thresholds for this symptom compared to non-COPD controls. Possible etiologies include systemic inflammation, central adaptations related to pain and dyspnea, and musculoskeletal conditions.\(^6\)

Among COPD patients, being aged between 70 and 79 years was associated with a higher risk of CNP than being aged between 35 and 59 years old. Regarding gender, female sex was a risk factor for CNP and CLBP. This finding is consistent with other authors who have also reported a higher prevalence of pain in women than in men.\(^2\)\(^1\) Christiansen et al.\(^1\)\(^1\) also reported a higher frequency of pain in women with COPD than in men with this disease. Possible explanations to justify the differences in pain between women and men include neuroimmunological, hormonal, genetic, and psychological factors.\(^2\)\(^2\) Furthermore, questions have also been raised as to whether men and women construct different meanings around pain, which may influence the way they report their experience of this symptom.\(^2\)\(^3\)

Previous studies have shown that mental disorders are positively associated with subsequent back/neck pain onset.\(^2\)\(^4\) We found higher probabilities of CNP in COPD patients with mental disorders, but we did not detect an association between mental disorders and CLBP. The
A relationship between migraine or severe headache and chronic health conditions, including COPD, has been reported in previous studies.29 Our study further confirms that suffering from migraine or frequent headache is a risk factor for CNP and CLBP among COPD patients. These results corroborate previous reports indicating that headache or migraine is often associated with other musculoskeletal pains, including neck and back pains.30,31 Furthermore, an increased number of comorbid pains has been significantly associated with a lower level of perceived general health.29

The probability of reporting CNP and CLBP in COPD patients in our study was significantly higher among pain medication users. Roberts et al32 reported that COPD patients have substantially more utilization of pain medications than those with most other chronic diseases. In addition, they found that compared with patients with chronic disease other than COPD, individuals with COPD had a 47% higher prevalence of chronic use of pain or pain-related outpatient prescription medications and a 27% higher prevalence of chronic use of short-acting or long-acting opioid medications.33
We did not find a relationship between obesity and physical activity with the appearance of CNP and CLBP in patients with COPD in our study. In contrast, HajGhanbart et al demonstrated that pain in the COPD population is associated with decreased physical activity and higher BMI. Pain-inducing activity limiting factors in these patients include comorbidities (ie, osteoporosis and osteoarthritis), specific medications (such as beta-2 agonists that can cause cramps in the calf muscles) and symptoms of deconditioning. However, we did not collect information on musculoskeletal comorbidities, medication for COPD or symptoms of deconditioning, so we cannot assess this relationship. On the other hand, it has been suggested that obesity increases the prevalence of pain by increasing pro-inflammatory cytokines and increasing the risk of osteoarthritis. In a vicious cycle, this symptom may also increase the risk of obesity by causing reductions in physical activity or hormonal changes.

The strengths of this population-based study include a matched case-control design, the use of standardized surveys, and training of the data collectors. A matched case-control design is effective to avoid the confounding effect of age, sex and province of residence. Furthermore, the novelty of our work is that we analyzed sociodemographic variables that are not collected in clinical records and self-reported lifestyles and pain characteristics, variables that are not usually collected with standardized methods in the clinical settings. Furthermore, we used a large (over 1000 subjects) representative sample of the entire Spanish population suffering from COPD rather than a selected sample from one or several hospitals or primary care centers; in our opinion, this provides great external validity to our results.

While the analysis was rigorous, our findings have several limitations. First, comorbid COPD and CLBP/CNP may have various causal links (ie, depression, discopathy, inflammation, overweight/obesity) and consequences (ie,
Table 3 Factors Associated with Suffering Chronic Neck Pain and Chronic Low Back Pain Among COPD Sufferers

|                          | Chronic Neck Pain | Chronic Low Back Pain |
|--------------------------|-------------------|-----------------------|
|                          | OR    | 95% CI | OR    | 95% CI |
| Age groups               |       |        |       |        |
| 35–59 years              | NS    | –      | 1     | –      |
| 60–69 years              | NS    | –      | 1.20  | 0.76   |
| 70–79 years              | NS    | –      | 1.67  | 1.08   |
| 80 or more               | NS    | –      | 1.12  | 0.72   |
| Sex                      |       |        |       |        |
| Man                      | 1     | 2.17   | 1     | 1.41   |
| Women                    |       | 1.57   |       | 1.03   |
|                           |       | 2.99   |       | 1.94   |
| Self-rated health        |       |        |       |        |
| Very good/good           | 1     | 1.87   | 1     | 1.84   |
| Fair/poor/very poor      |       | 1.28   |       | 1.31   |
|                           |       | 2.73   |       | 2.47   |
| Mental disorder          |       |        |       |        |
| No                       | 1     | 1.43   | NS    | –      |
| Yes                      |       | 1.00   | NS    | –      |
|                           |       | 2.05   |       | –      |
| Use of pain medication   |       |        |       |        |
| No                       | 1     | 2.12   | 1     | 2.05   |
| Yes                      |       | 1.51   |       | 1.48   |
|                           |       | 2.97   |       | 2.84   |
| Migraine or frequent headache |   |       |       |        |
| No                       | 1     | 1.56   | 1     | 1.83   |
| Yes                      |       | 1.01   |       | 1.16   |
|                           |       | 2.41   |       | 2.89   |
| Concomitant chronic neck pain |   |       |       |        |
| No                       | NIM   | –      | 1     | 8.44   |
| Yes                      | NIM   | –      |       | 6.09   |
|                           |       | –      |       | 11.71  |
| Concomitant chronic low back pain |   |       |       |        |
| No                       | NIM   | –      | NIM   | –      |
| Yes                      | NIM   | –      |       | –      |

Abbreviations: NS, not significant; NIM, not included in the final model; OR, odds ratios estimated using multivariable unconditional logistic regression; CI, confidence interval.

reduction in physical activity, therapy compliance, quality of life), which could not be fully investigated given the limited information collected by the SNHS2017. Furthermore, cross-sectional designs suffer from the possibility of reverse causality bias; therefore, we can identify significant associations but not establish risk factors or causality. Further prospective studies with more clinical variables are needed to confirm our results. Second, the only source to assess information on the types of pain analyzed is self-reporting; therefore, under- or over-reporting may appear because of recall, information or social desirability biases. Third, we were able to adjust for a large number of potential confounding factors in the multivariate analyses, but the possibility of residual confounding by unrecognized factors cannot be definitively ruled out. Fourth, the specific characteristics of COPD are not collected in the SNHS2017, including severity of airway obstruction, disease duration or treatments. However, none of the included studies on pain or symptom burden in a recent meta-analysis reported a significant relationship between lung function and pain prevalence or severity.14 Fifth, the validity of the self-reported conditions included in the SNHS2017 has not been evaluated, which could have resulted in misclassification of patients in the analysis.

Conclusions

In conclusion, the prevalence of CNP and CLBP was significantly higher among COPD patients than among non-COPD controls. In addition, suffering one of the pains greatly increased the risk of having the other and vice versa. Associated factors with suffering these types of pain among COPD subjects included age 70 to 79 years (only for CLBP), being female, having mental disorder (only for CNP), having worse self-rated health, suffering migraine or frequent headache, and using pain medication. Our findings add new data to the knowledge of chronic pain in COPD patients and justify its inclusion in clinical practice guidelines for this disease.

Funding

This study is a part of the research funded by: a) SEPAR (Sociedad Española de Neumología y Cirugía Torácica): project no.733 of the 2018 edition; and b) NEUMOMADRID (Sociedad Madrileña de Neumología y Cirugía de Tórax): XVIII Awards Edition, 2018. Finally, this work was also
supported by the FIS (Fondo de Investigaciones Sanitarias—Health Research Fund, Instituto de Salud Carlos III) co-financed by the European Union through the Fondo Europeo de Desarrollo Regional (FEDER, “Una manera de hacer Europa”); grant no. PI16/00564.

Disclosure

The authors declare no conflicts of interest.

References

1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2020. Available from: https://www.goldcopd.org. Accessed April 27, 2020.

2. Brown R. Control of COPD symptoms: addressing an unmet need. J Fam Pract. 2016;65(12 Suppl).

3. De Miguel Diez J, Jiménez García R, López de Andrés A. Living with COPD: pain is important too. Arch Bronconeumol. 2019;56(6):351–352.

4. Chen YW, Camp PG, Coxson HO, et al. Comorbidities that cause pain and the contributors to pain in individuals with chronic obstructive pulmonary disease. Arch Phys Med Rehabil. 2017;98:1535–1543. doi:10.1016/j.apmr.2016.10.016

5. Bentsen SB, Rustoen T, Miaskowski C. Prevalence and characteristics of pain in patients with chronic obstructive pulmonary disease compared to the Norwegian general population. J Pain. 2011;12:539–545. doi:10.1016/j.jpain.2010.10.014

6. HajGarbani B, Holsti L, Road JD, et al. Pain in people with chronic obstructive pulmonary disease (COPD). Respir Med. 2012;106:998–1005. doi:10.1016/j.rmed.2012.03.004

7. Borge CR, Wahl AK, Moun T. Pain and quality of life with chronic obstructive pulmonary disease. Heart Lung. 2011;40:90–101. doi:10.1016/j.hrtlng.2010.10.009

8. Lewthwaite H, Williams G, Baldock KL, et al. Systematic review of pain in clinical practice guidelines for management of COPD: a case for including chronic pain? Healthcare (Basel). 2019;7:15. doi:10.3390/healthcare7010015

9. Bentsen SB, Miaskowski C, Cooper BA, et al. Distinct pain profiles in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2018;13:801–811. doi:10.2147/COPD.S150114

10. Bordoni B, Marelli F, Morabito B, et al. Chest pain in patients with COPD: the fascia’s subtle silence. Int J Chron Obstruct Pulmon Dis. 2018;13:1157–1165. doi:10.2147/COPD.S136729

11. Christensen VL, Holm AM, Kongerud J, et al. Occurrence, characteristics, and predictors of pain in patients with chronic obstructive pulmonary disease. Pain Manag Nurs. 2016;17:107–118. doi:10.1016/j.pmn.2016.01.002

12. Johnson AM, Smith SM. A review of general pain measurement tools and instruments for consideration of use in COPD clinical practice. Int J Chron Obstruct Pulmon Dis. 2017;12:923–929. doi:10.2147/COPD.S119889

13. De Miguel-diez J, López-de-Andrés A, Hernandez-Barrera V, et al. Prevalence of pain in COPD patients and associated factors: report from a population-based study. Clin J Pain. 2018;34:787–794. doi:10.1097/AJP.0000000000000598

14. Van Dam van Isselt EF, Groenevegen-Sipkema KH, Spruit-van Eijk M, et al. Pain in patients with COPD: a systematic review and meta-analysis. BMJ Open. 2014;4:e005898. doi:10.1136/bmjopen-2014-005898

15. Instituto Nacional de Estadística. Encuesta Nacional de Salud 2017. [National health survey 2017]. Available from: https://www.ine.es/en/metodologia/t15/t153041917_en.pdf. Accessed March 11, 2020.

16. Force GT. Clinical practice guideline for the diagnosis and treatment of patients with chronic obstructive pulmonary disease (COPD) – the Spanish COPD guideline (GesEPOC). Arch Bronconeumol. 2017;53:S2–S64.

17. Instituto Nacional de Estadística. Encuesta Nacional de Salud 2017. Cuestionario de adultos [National health survey 2017. Adults questionnaire]. Available from: https://www.ine.es/metodologia/t15/ense_adult.pdf. Accessed March 11, 2020.

18. Hosmer DW, Lemeshow S, Sturdivant RX. Applied Logistic Regression. 3rd ed. New York, USA: John Wiley & Sons, Inc; 2013.

19. Ministerio de Sanidad Consumo y Bienestar Social. Encuesta Nacional de Salud 2017. Microdatos. [National health survey 2017. Microdata]. Available from: https://www.mscbs.gob.es/estadisticas/microdatos.do. Accessed March 11, 2020.

20. Sánchez Castillo S, Smith L, Díaz Suárez A, et al. Associations between physical activity and comorbidities in people with COPD residing in Spain: a cross-sectional analysis. Int J Environ Res Public Health. 2020;17(2):594. doi:10.3390/ijerph17020594

21. Bartley EJ, Fillingim RB. Sex differences in pain: a brief review of clinical and experimental findings. Br J Anaesth. 2013;111:52–58. doi:10.1093/bja/aet127

22. Anderaas R, Momyr A, Brekke I. Reporting of pain by people with chronic obstructive pulmonary disease (COPD): comparative results from the HUNT3 population-based survey. BMC Public Health. 2018;18:181. doi:10.1186/s12889-018-5094-5

23. Unruh AM. Gender variations in clinical pain experience. Pain. 1996;65:123–167. doi:10.1016/0304-3959(95)00214-6

24. Viana MC, Lim CCW, Garcia Pereira F, et al. Previous mental disorders and subsequent onset of chronic back or neck pain: findings from 19 countries. J Pain. 2018;19:99–110. doi:10.1016/j.jpain.2017.08.011

25. Elman I, Zubieta JK, Borsook D. The missing p in psychiatric training: why it is important to teach pain to psychiatrists. Arch Gen Psychiatry. 2011;68:12–20. doi:10.1001/archgenpsychiatry.2010.174

26. Janssen DJ, Wouters EF, Parra YL, et al. Prevalence of thoracic pain in patients with chronic obstructive pulmonary disease and relationship with patient characteristics: a cross-sectional observational study. BMC Pulm Med. 2016;16:47. doi:10.1186/s12890-016-0210-8

27. Lee AL, Goldstein RS, Brooks D. Chronic pain in people with chronic obstructive pulmonary disease: prevalence, clinical and psychological implications. Chronic Obstr Pulm Dis. 2017;4:194–203.

28. Van Dam van Isselt EF, Groenevegen-Sipkema KH, van Eijk M, et al. Pain in patients with chronic obstructive pulmonary disease indicated for post-acute pulmonary rehabilitation. Chron Respir Dis. 2019;16:1479972318809456. doi:10.1177/1479972318809456

29. Minn MT, Weissman J, Tietjen GE. The relationship between migraine or severe headache and chronic health conditions: a cross-sectional study from the national health interview survey 2013–2015. Pain Med. 2019;20:2263–2271. doi:10.1093/pm/pnz113

30. Scher AI, Bigal ME, Lipton RB. Comorbidity of migraine. Curr Opin Neurol. 2005;18:305–310. doi:10.1097/01.wco.0000169750.52406.a2

31. Scher AI, Stewart WF, Lipton RB. The comorbidity of headache with other pain syndromes. Headache. 2006;46:1416–1423. doi:10.1111/j.1526-4610.2006.00584.x

32. Roberts MH, Mapel DW, Thomson HN. The impact of chronic pain on direct medical utilization and costs in chronic obstructive pulmonary disease. Clinicoecon Outcomes Res. 2015;7:173–184. doi:10.2147/CEOR.S80424

33. Roberts MH, Mapel DW, Hartry A, et al. Chronic pain and pain medication use in chronic obstructive pulmonary disease. A cross-sectional study. Ann Am Thorac Soc. 2013;10:290–298. doi:10.1513/AnnalsATS.201303-040OC

34. Ferguson GT, Calverley PMA, Anderson JA, et al. Prevalence and progression of osteoporosis in patients with COPD: results from the towards a revolution in COPD health study. Chest. 2009;136:1456–1465. doi:10.1378/chest.08-3016
35. O’Donnell DE, Hernandez P, Kaplan A, et al. Canadian thoracic society recommendations for management of chronic obstructive pulmonary disease - 2008 update - highlights for primary care. Can Respir J. 2008;15:1A–8A.

36. Wagner PD. Skeletal muscles in chronic obstructive pulmonary disease: deconditioning, or myopathy? Respir Med. 2006;11:681–686. doi:10.1111/j.1440-1843.2006.00939.x

37. Steultjens MP, Dekker J, van Baar ME, et al. Muscle strength, pain and disability in patients with osteoarthritis. Clin Rehabil. 2001;15:331–341. doi:10.1111/0269-2155.2001.tb01784.0